Finasteride and Minoxidil: What the Trials Actually Show

Male pattern hair loss is, oddly, the best-evidenced subject on this site. Two drugs are FDA-approved for it, both have been through large randomised trials, and the numbers are public. That’s unusual here — most of what men search for at 1am rests on far weaker ground.

What is actually happening

Androgenetic alopecia is not hair falling out so much as hair getting smaller. Under the influence of dihydrotestosterone (DHT), susceptible follicles miniaturise over successive cycles: each new hair comes in finer, shorter and less pigmented, until it stops breaking the surface at all.

Two things follow from that, and they explain almost everything about treatment.

The earlier you intervene, the more there is to save. A miniaturised follicle can often be pushed back toward normal. A follicle that has been dormant for years is a much harder proposition.

Nothing you do is permanent. Both drugs work by holding back an ongoing process. Stop, and the process resumes from wherever it had got to.

Finasteride: what the trials showed

Finasteride 1 mg blocks the enzyme that converts testosterone to DHT. The FDA labelling for Propecia reports the pivotal trial results directly, and they’re worth reading in the original units rather than in percentages someone else chose.

At twelve months, in a one-inch circle on the scalp, there was a 107-hair difference between finasteride and placebo (n=679 vs 672, p<0.001).

That second row is the one most men miss. The headline benefit of finasteride is not regrowth — it’s that 86% of men on it did not continue losing, against 42% on placebo. It is far better at keeping hair than at bringing it back.

Improvement was measurable from three months, though the visible answer takes longer.

The side-effect question, honestly

This is where most writing on the subject goes wrong in one of two directions: the clinics wave it away, and the forums treat it as certain catastrophe. The evidence supports neither.

What the trials found. In the first year of the pivotal studies:

Note how much of the effect shows up in the placebo arm. Roughly a percentage point separates drug from sugar pill on each measure. That doesn’t mean the difference isn’t real — it means it is small, and it means a meaningful share of men who report these symptoms on finasteride would have reported them anyway.

What is genuinely unresolved. Post-finasteride syndrome describes sexual, cognitive and mood symptoms persisting after the drug is stopped. A 2025 review of the literature is blunt about the state of the evidence: the exact prevalence is unknown, because no epidemiological study has established it. No medical society has even proposed a formal definition. The available studies suffer from selection bias, self-reporting bias, recall bias, absent control groups, and no objective biomarker to diagnose against. Symptoms also appear in placebo arms, which makes causation genuinely hard to establish.

On the other side of the ledger, a 2020 meta-analysis found that 5-alpha reductase inhibitors increased the risk of PFS-like adverse effects by 1.87 times compared with placebo.

The honest summary: something appears to be happening in a small number of men, nobody has established how often, and the research needed to settle it has not been done. Anyone who tells you the risk is precisely zero is overstating the evidence. So is anyone who quotes you a scary percentage — that number does not exist.

Minoxidil: real, modest, and forever

Topical minoxidil works by a different route — it appears to prolong the growth phase and improve blood flow to the follicle rather than touching hormones at all. That makes it usable alongside finasteride, and usable by men who don’t want to go near a DHT blocker.

The individual trials are generally small. One study of 5% foam followed 17 men, of whom 12 completed 24 weeks; average hair count in the measured area rose from about 163 at baseline to about 195 at 24 weeks, and three-quarters of participants said their hair loss had improved. Side effects were limited to mild scalp itching.

Treat those specifics with the caution a twelve-man completion cohort deserves. The reason minoxidil is nonetheless a mainstream recommendation is the weight of decades of use and FDA approval behind it, not any single decisive trial.

The practical catch is adherence. Twice daily, indefinitely, on a scalp that may itch — most people who fail on minoxidil fail by stopping.

Using both together

Because the two work by unrelated mechanisms, combining them is standard practice. A 2025 meta-analysis of seven randomised trials in 396 men compared a topical minoxidil-finasteride solution against minoxidil alone and found the combination better on hair density (mean difference 9.22, p=0.04), hair diameter (2.26, p=0.005) and global assessment (0.79, p<0.00001). Men on the combination were more than three times as likely to achieve marked improvement (OR 3.29, p=0.015).

One interesting wrinkle: applied topically at follicular concentrations, finasteride keeps blood levels below the threshold associated with sexual dysfunction, and the trials in that review reported no treatment-emergent sexual adverse events. That is a promising signal rather than a settled finding — the studies are small and short. Contact dermatitis appeared in 12–24% of cases, usually manageable.

What the evidence does not support

Biotin, if you are not deficient. Biotin supplementation helps hair in people with a genuine biotin deficiency, which is rare. It does not treat androgenetic alopecia. It does interfere with some lab assays, including troponin, which is a real clinical problem.

Saw palmetto as a finasteride substitute. The mechanism is superficially similar and the evidence is far weaker. If you want a 5-alpha reductase inhibitor, the one with the trial data is available on prescription.

Shampoos, in general. A ketoconazole shampoo has some supporting data and may help scalp condition. Nothing you rinse off after ninety seconds is going to reverse miniaturisation.

Anything promising results in weeks. The hair cycle does not move that fast.

What to expect, and when

• Months 0–3: possibly increased shedding as follicles are pushed into a new cycle. This is normal and is not the drug making things worse.
• Months 3–6: the first measurable changes. Not usually the first visible ones.
• Months 6–12: where the trial results were measured, and where you should judge it.
• Indefinitely: maintenance. Stopping returns you to the trajectory you were on.

Take standardised photographs at the start — same light, same angle, same parting. Judging your own hairline in a bathroom mirror over twelve months is close to useless, and the photographs are the only thing that will tell you whether it worked.

When to see a doctor rather than order online

• Hair loss that is patchy, sudden, or comes with scalp pain, scaling or redness — that is not male pattern baldness and needs a diagnosis
• Loss accompanied by fatigue, weight change or other systemic symptoms — thyroid disease and iron deficiency both cause shedding
• You are trying to conceive, or may be soon
• You are already on other medication, or have a history of depression — worth discussing before starting

This article is for information only and is not medical advice. It cannot account for your individual circumstances. Talk to a doctor about your own situation, particularly before starting or stopping any prescription medication.